Is NO an endogenous antiatherogenic molecule? - PubMed (original) (raw)
Editorial
Is NO an endogenous antiatherogenic molecule?
J P Cooke et al. Arterioscler Thromb. 1994 May.
No abstract available
Comment on
- Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits.
Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Cayatte AJ, et al. Arterioscler Thromb. 1994 May;14(5):753-9. doi: 10.1161/01.atv.14.5.753. Arterioscler Thromb. 1994. PMID: 7513551 - Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium-dependent relaxation.
Naruse K, Shimizu K, Muramatsu M, Toki Y, Miyazaki Y, Okumura K, Hashimoto H, Ito T. Naruse K, et al. Arterioscler Thromb. 1994 May;14(5):746-52. doi: 10.1161/01.atv.14.5.746. Arterioscler Thromb. 1994. PMID: 8172852
Similar articles
- [Antiatherogenic effects of endothelium-derived relaxing factor (nitric oxide)].
Iturry-Yamamoto G, Alves AA, Picon PD. Iturry-Yamamoto G, et al. Arq Bras Cardiol. 1997 Nov;69(5):349-57. doi: 10.1590/s0066-782x1997001100010. Arq Bras Cardiol. 1997. PMID: 9609003 Review. Portuguese. No abstract available. - [Vasoprotection through vascular nitric oxide. Molecular basis of antiatherosclerotic actions].
Müller S, Gewaltig MT, Kojda G. Müller S, et al. Med Monatsschr Pharm. 2002 Feb;25(2):45-51. Med Monatsschr Pharm. 2002. PMID: 11881329 Review. German. No abstract available. - Nitric oxide: an endogenous cardioprotectant?
Pabla R, Curtis MJ. Pabla R, et al. EXS. 1996;76:71-85. doi: 10.1007/978-3-0348-8988-9_5. EXS. 1996. PMID: 8805789 Review. No abstract available. - Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit.
Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Cooke JP, et al. J Clin Invest. 1992 Sep;90(3):1168-72. doi: 10.1172/JCI115937. J Clin Invest. 1992. PMID: 1522225 Free PMC article. - The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits.
Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S. Holm P, et al. Circulation. 1999 Oct 19;100(16):1727-33. doi: 10.1161/01.cir.100.16.1727. Circulation. 1999. PMID: 10525493
Cited by
- Endothelial function as measured by peripheral arterial tonometry increases during pubertal advancement.
Bhangoo A, Sinha S, Rosenbaum M, Shelov S, Ten S. Bhangoo A, et al. Horm Res Paediatr. 2011;76(4):226-33. doi: 10.1159/000328455. Epub 2011 Jul 22. Horm Res Paediatr. 2011. PMID: 21778688 Free PMC article. - Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease.
Fujii H, Kono K, Yamamoto T, Onishi T, Goto S, Nakai K, Kawai H, Hirata KI, Fukagawa M, Nishi S. Fujii H, et al. Clin Kidney J. 2012 Dec;5(6):512-518. doi: 10.1093/ckj/sfs114. Epub 2012 Oct 3. Clin Kidney J. 2012. PMID: 24976967 Free PMC article. - Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults.
Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE. Clarkson P, et al. J Clin Invest. 1996 Apr 15;97(8):1989-94. doi: 10.1172/JCI118632. J Clin Invest. 1996. PMID: 8621785 Free PMC article. Clinical Trial. - Endothelial nitric oxide (NO) and its pathophysiologic regulation.
Chatterjee A, Black SM, Catravas JD. Chatterjee A, et al. Vascul Pharmacol. 2008 Oct-Dec;49(4-6):134-40. doi: 10.1016/j.vph.2008.06.008. Epub 2008 Jul 20. Vascul Pharmacol. 2008. PMID: 18692595 Free PMC article. Review. - Role of nitric oxide in progression and regression of atherosclerosis.
Cooke JP. Cooke JP. West J Med. 1996 May;164(5):419-24. West J Med. 1996. PMID: 8686299 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources